ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.920,86
-1,20%
S&P 500
5.205,49
0,34%
US Dollar vs BRL
5,1546
1,28%
Bitcoin
62.054,84
1,42%
Brent Oil
83,545
-0,02%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Oaktree Acquisition Corp II (OACB)

  7. Oaktree Acquisition Corp II (OACB) Notícias

OACB

Oaktree Acquisition Corp... (OACB)

Oaktree Acquisition Corp II
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:OACB
DataHoraFonteTítuloCódigoCompanhia
15/06/202212:36Edgar (US Regulatory)Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)NYSE:OACBOaktree Acquisition Corp II
09/06/202208:10Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NYSE:OACBOaktree Acquisition Corp II
08/06/202222:16Business WireAlvotech und Oaktree Acquisition Corp. II melden Zustimmung der Aktionäre zum UnternehmenszusammenschlussNYSE:OACBOaktree Acquisition Corp II
08/06/202206:54Business WireAlvotech et Oaktree Acquisition Corp. II annoncent l'approbation des actionnaires pour le regroupement d'entreprisesNYSE:OACBOaktree Acquisition Corp II
07/06/202217:00Business WireAlvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business CombinationNYSE:OACBOaktree Acquisition Corp II
03/06/202218:29Edgar (US Regulatory)Current Report Filing (8-k)NYSE:OACBOaktree Acquisition Corp II
03/06/202218:17Business WireOaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with AlvotechNYSE:OACBOaktree Acquisition Corp II
24/05/202208:00Business WireAlvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®NYSE:OACBOaktree Acquisition Corp II
16/05/202216:08Edgar (US Regulatory)Quarterly Report (10-q)NYSE:OACBOaktree Acquisition Corp II
16/05/202209:00Business WireAlvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®NYSE:OACBOaktree Acquisition Corp II
11/05/202209:00Business WireAlvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business CombinationNYSE:OACBOaktree Acquisition Corp II
10/05/202219:34Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NYSE:OACBOaktree Acquisition Corp II
20/04/202218:00Business WireAlvotech améliore son accès aux capitaux et optimise son processus d’entrée en bourse, prévue sur le NASDAQNYSE:OACBOaktree Acquisition Corp II
20/04/202213:45Business WireAlvotech verbessert Zugang zu Kapital und ebnet Weg für erwartete NASDAQ-NotierungNYSE:OACBOaktree Acquisition Corp II
20/04/202209:15Business WireAlvotech migliora l'accesso al capitale e semplifica il percorso verso la prevista quotazione in Borsa al NASDAQNYSE:OACBOaktree Acquisition Corp II
19/04/202219:00Business WireAlvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock ExchangeNYSE:OACBOaktree Acquisition Corp II
08/04/202211:01Business WireアルヴォテックとSTADA、アッヴィとの欧州特許紛争を解決してHumira®のクエン酸フリー高濃度バイオシミラーHUKYNDRA®（AVT02）発売への道を開くNYSE:OACBOaktree Acquisition Corp II
06/04/202222:15Business WireAlvotech et STADA ouvrent la voie au lancement de HUKYNDRA® (AVT02), un biosimilaire de l'Humira® haute concentration sans citrate, en réglant le litige de brevet européen qui les opposait à AbbVieNYSE:OACBOaktree Acquisition Corp II
06/04/202219:21Business WireAlvotech und STADA ebnen durch Beilegung des europäischen Patentstreits mit AbbVie den Weg für die Markteinführung von HUKYNDRA®(AVT02), einem zitratfreien, hochkonzentrierten Biosimilar zu Humira®NYSE:OACBOaktree Acquisition Corp II
06/04/202208:00Business WireAlvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVieNYSE:OACBOaktree Acquisition Corp II
14/03/202208:10Business Wireアルヴォテックがアッヴィとの米国特許・企業秘密紛争を解決し、Humira®向けにアルヴォテックが提案中の高濃度バイオシミラー（AVT02）の米国での権利を確保NYSE:OACBOaktree Acquisition Corp II
09/03/202219:44Business WireAlvotech legt US-Patent- und Geschäftsgeheimnisstreitigkeiten mit AbbVie bei und sichert sich US-Rechte für von Alvotech geplantes hochkonzentriertes Biosimilar (AVT02) zu Humira®NYSE:OACBOaktree Acquisition Corp II
09/03/202214:03Business WireAlvotech règle les litiges portant sur des brevets et des secrets commerciaux qui l’opposaient à AbbVie aux États-Unis et garantit ainsi les droits américains pour le biosimilaire à l’Humira® haute concentration (AVT02) proposé par AlvotechNYSE:OACBOaktree Acquisition Corp II
08/03/202219:06Business WireAlvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Rights for Alvotech’s Proposed High-Concentration Biosimilar (AVT02) for Humira®NYSE:OACBOaktree Acquisition Corp II
16/02/202218:14Edgar (US Regulatory)Statement of Ownership (sc 13g)NYSE:OACBOaktree Acquisition Corp II
07/02/202218:46Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:OACBOaktree Acquisition Corp II
20/01/202212:15Business WireAlvotech augmente le montant de transaction PIPE sursouscrite qui s’approche désormais de 175 millions USDNYSE:OACBOaktree Acquisition Corp II
19/01/202213:18Business WireAlvotech vergrößert überzeichnete PIPE-Transaktion auf ca. 175 Mio. USDNYSE:OACBOaktree Acquisition Corp II
18/01/202218:01Business WireAlvotech Upsizes Oversubscribed PIPE Transaction to Approximately $175 MillionNYSE:OACBOaktree Acquisition Corp II
13/12/202118:10Edgar (US Regulatory)Amended Quarterly Report (10-q/a)NYSE:OACBOaktree Acquisition Corp II
 Apresentando as notícias mais relevantes sobre:NYSE:OACB

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
OIBR3
OI ON
BOV
PDTC3
Padtec ON
BOV
AZEV4
AZEVEDO PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
PRIO3
PETRORIO ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
VVEO3
CM Hospitalar ON
BOV
ENJU3
Enjoei ON
BOV
JHSF3
JHSF PART ON
BOV
SGPS3
SPRINGS ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
PDGR3
PDG REALT ON
BOV
FNAM11
Fundo Invest Amazonia Fi...
BOV
BRKM5
BRASKEM PNA
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados